Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

[Using resource groups in assertive community treatment; literature review and recommendation].

Smeerdijk M, Delespaul PHAEG, Keet IPM, Nugter MA.

Tijdschr Psychiatr. 2017;59(8):466-473. Dutch.

2.

[Functional remission of people with serious mental illness (SMI): psychometric properties of a new ROM-instrument].

Wiersma D, Visser E, Bähler M, Bruggeman R, Delespaul PA, van der Gaag M, de Haan L, Keet IP, Nijssen Y, van Os J, Pijnenborg GH, Slooff C, Swildens W, de Vos AE, van Weeghel J, Wunderink L, Mulder CL.

Tijdschr Psychiatr. 2015;57(6):395-404. Dutch.

3.

[Come across to improve the treatment of severe metal illness].

Keet IP.

Tijdschr Psychiatr. 2014;56(11):706-7. Dutch. No abstract available.

4.

[The last book issue].

Keet IP, Dom G.

Tijdschr Psychiatr. 2013;55(12):924. Dutch. No abstract available.

5.

[Recovery].

Keet IP.

Tijdschr Psychiatr. 2013;55(12):921-3. Dutch. No abstract available.

6.

Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial.

Czobor P, Volavka J, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW; EUFEST Study Group.

J Clin Psychopharmacol. 2013 Apr;33(2):258-61. doi: 10.1097/JCP.0b013e3182856886. No abstract available.

PMID:
23422388
7.

Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.

Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS; Eufest Study Group.

Eur Neuropsychopharmacol. 2013 Mar;23(3):196-204. doi: 10.1016/j.euroneuro.2012.04.019. Epub 2012 May 28.

PMID:
22647933
8.

Familial sinistrality and handedness in patients with first episode schizophrenia: the EUFEST study.

Dollfus S, Alary M, Razafimandimby A, Prelipceanu D, Rybakowski JK, Davidson M, Galderisi S, Libiger J, Hranov LG, Hummer M, Boter H, Peuskens J, Kahn RS, Fleischhacker WW; EUFEST Group.

Laterality. 2012;17(2):217-24. doi: 10.1080/1357650X.2011.558510. Epub 2011 Sep 14.

PMID:
22385143
9.

[ROM: primarily an instrument for treat].

Keet IP, Nugter MA, Hafkenscheid A, Van Den Eede F, Thunnissen MM.

Tijdschr Psychiatr. 2012;54(2):107-9. Dutch. No abstract available.

10.

[Getting better at home, not in the hospital].

Keet IP.

Tijdschr Psychiatr. 2011;53(10):691-3. Dutch. No abstract available.

11.

Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse?

Derks EM, Fleischhacker WW, Boter H, Peuskens J, Kahn RS; EUFEST Study Group.

J Clin Psychopharmacol. 2010 Apr;30(2):176-80. doi: 10.1097/JCP.0b013e3181d2193c.

PMID:
20520291
12.

Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).

Gaebel W, Riesbeck M, von Wilmsdorff M, Burns T, Derks EM, Kahn RS, Rössler W, Fleischhacker WW; EUFEST Study Group.

Eur Neuropsychopharmacol. 2010 May;20(5):310-6. doi: 10.1016/j.euroneuro.2010.02.001. Epub 2010 Mar 3.

PMID:
20202800
13.

Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST).

Boter H, Derks EM, Fleischhacker WW, Davidson M, Kahn RS; EUFEST Study Group.

J Clin Psychiatry. 2010 Jan;71(1):58-65. doi: 10.4088/JCP.08m04506yel. Epub 2009 Oct 20.

PMID:
19852905
14.

Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study.

Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, Rybakowski JK, Libiger J, Dollfus S, López-Ibor JJ, Peuskens J, Hranov LG, Fleischhacker WW; EUFEST group.

Schizophr Res. 2009 Dec;115(2-3):104-14. doi: 10.1016/j.schres.2009.09.022. Epub 2009 Oct 12.

PMID:
19822407
15.

Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).

Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS.

Am J Psychiatry. 2009 Jun;166(6):675-82. doi: 10.1176/appi.ajp.2008.08060806. Epub 2009 Apr 15. Erratum in: Am J Psychiatry. 2009 Jun;166(6):731.

PMID:
19369319
16.

[Severe mental illness: cure and care?].

Keet IP.

Tijdschr Psychiatr. 2008;50(9):555-7. Dutch. No abstract available.

17.

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.

Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST study group.

Lancet. 2008 Mar 29;371(9618):1085-97. doi: 10.1016/S0140-6736(08)60486-9.

PMID:
18374841
18.

[Delirium on re-starting clozapine after a short break in treatment].

Benckhuijsen JA, Keet IP.

Tijdschr Psychiatr. 2007;49(9):661-5. Dutch.

19.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Fleischhacker WW, Keet IP, Kahn RS; EUFEST Steering Committee.

Schizophr Res. 2005 Oct 15;78(2-3):147-56.

PMID:
16055308
20.

[Lithium, a potentially dangerous drug].

van der Goot B, Hagen EC, Keet IP, Wernand J.

Ned Tijdschr Geneeskd. 2005 Apr 30;149(18):1018; author reply 1018-9. Dutch. No abstract available.

PMID:
15903048

Supplemental Content

Loading ...
Support Center